Market Access Strategy for Medical Devices in Europe
Strategic recommendations on the topic of market access pathways for medical devices and IVD tests
Recent news and posts
Regular update of the Norwegian Laboratory Code System released
On March 23, 2025, the Norwegian Directorate of Health released an updated version of the Norwegian Laboratory Code (NLK) system (Norsk laboratoriekodeverk 7280.75) and associated tariffs (Laboratoriekodeverk som gir rett til refusjon) for state and private laboratories to be implemented no later than May 1, 2025. NLK system is used for activity-based reimbursement by the Norwegian Health Economics Administration (Helfo) for laboratory tests performed in outpatient settings.
A total of 143 new codes were added, 10 codes were removed, and 72 codes were changed.
Some examples of newly introduced codes are provided below:
- NPU62974 P-Glycylproline;
- NPU62979 Sp-Glycylproline;
- NPU62986 U-Glycylproline/Creatine;
- NPU63073 B-11OH Testosterone;
- NPU63075 DNA(B)-CALR gene (NG_029662.1:g.10159_10210del);
- NPU63134 Spytt-Metanephrine;
- NPU63017 P-Hepatitis E virus (HEV) RNA;
- NPU63142 Us-Helicobacter pylori (DNA; Levofloxacin resistance);
- NPU63034 Lymc(B)-NK-cells %;
- NPU28413 P-Intrinsic factor IgG.
The letter at the beginning of the code description stands for sample type: B – blood, P – plasma, Sp – spinal fluid, Spytt – Saliva, U – urine, Us – unspecified sample.
See the full details in Norwegian here and here.
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.